Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of INCA33890 in advanced or metastatic solid tumors
jRCT2031240610Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Feb 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of INCA-33890 in Nonhematologic neoplasms (10 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities, Treatment Emergent Adverse Events and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
INCA-33890
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240610.